Pharmacological Treatment of Underactive Bladder
| Autor: | K. E. Andersson |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Distigmine
Carbachol business.industry 030232 urology & nephrology Bethanechol Pharmacology Underactive bladder medicine.disease 03 medical and health sciences Transient receptor potential channel 0302 clinical medicine 030220 oncology & carcinogenesis Muscarinic acetylcholine receptor medicine Esterase inhibitor business Acetylcholine medicine.drug |
| Zdroj: | Underactive Bladder ISBN: 9783319430850 |
| DOI: | 10.1007/978-3-319-43087-4_6 |
| Popis: | Current standard pharmacotherapy for underactive bladder (UAB) and detrusor underactivity (DUA) includes muscarinic receptor agonists, such as bethanechol and carbachol to stimulate detrusor muscarinic receptors, choline esterase inhibitors, like distigmine to reduce the degradation of acetylcholine, and α-adrenoceptor antagonists to block α-adrenoceptors in the outflow region. α-Adrenoceptor antagonists may have a beneficial effect on UAB/DUA in some cases of functional outflow obstruction, caused by benign prostatic hyperplasia or neurogenic bladder, however, available information shows that little clinically useful effect of muscarinic receptor agonists or choline esterase inhibitors can be obtained in preventing or treating the condition. Other types of drug, such as transient receptor potential channel agonists and prostanoids have so far had no or limited success. Even if theoretically the condition can be improved by agents that increase detrusor contractile activity and decrease bladder capacity, and/or decrease outlet resistance, the multifactorial pathophysiology of UAB/DUA, involving both central and peripheral factors, has to be considered, and to be successful, therapy has to be directed to both the major mechanism involved and to the associated morbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|